SUN08 Phenotyping Generalized Pustular Psoriasis (GPP): Findings of a collaborative Artificial Intelligence (AI) Initiative
DESCRIPTION
This session will present how innovative AI modeling can identify a distinct generalized pustular psoriasis (GPP) phenotype comprising data elements from patients' health histories. This phenotype can distinguish GPP patients who may otherwise remain undiagnosed from the broader population, providing clinical insight and the potential for reduced time to diagnosis and treatment. Such innovations can be applied to help recognize other rare diseases, allowing earlier access to treatment, and ultimately decrease patient suffering.
LEARNING OBJECTIVES
Demonstrate how a heterogeneous open claims data source augmented with EHR data, can be used to identify patients with Generalized Pustular Psoriasis (GPP).
Describe characteristics of GPP patients versus general psoriasis patients in a defined cohort.
Examine how AI can be used to isolate rare disease profiles to identify patients for early intervention and targeted treatment
SCHEDULE
7:30 AM
Introduction: Data Derm and AI
Marta Jane Van Beek, MD, MPH, FAAD
7:40 AM
GPP: The Patient Journey
Tina Bhutani, MD, FAAD, Lawrence J Green, MD, FAAD, Elizabeth A. Kiracofe, MD, FAAD
8:05 AM
Digital Phenotyping in AI for Early Diagnosis & Intervention for GPP
Joseph Zabinski, PhD
DIRECTOR
Marta Jane Van Beek, MD, MPH, FAAD
University of Iowa Health Care
SPEAKERS
Tina Bhutani, MD, FAAD
Lawrence J Green, MD, FAAD
Elizabeth A. Kiracofe, MD, FAAD
Airia Comprehenisve Dermatology
Joseph Zabinski, PhD
OM1, Inc.
DISCLOSURES
Tina Bhutani, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Amgen – Investigator(Grants/Research Funding), Speaker(Honoraria); Apogee BioPharm – Advisory Board(Honoraria); Arcutis Biotherapeutics – Speaker(Honoraria); Arcutis, Inc. – Advisory Board(Fees); ASLAN Pharmaceuticals – Data Safety Monitoring Board(Fees), Data Safety Monitoring Board(Honoraria); Boehringer Ingelheim – Advisory Board(Fees); Bristol Myers Squibb – Speaker(Honoraria); Bristol-Myers Squibb – Advisory Board(Fees); Castle Biosciences – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Celgene – Investigator(Grants/Research Funding); Clementia Pharmaceuticals – Investigator(Grants/Research Funding); CoreEvitas, LLC – Investigator(Grants/Research Funding); Dermatology Foundation – Speaker(Honoraria); Dermavant Sciences – Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Eli Lilly and Company – Advisory Board(Fees); FIDE – Consultant(Fees); Galderma – Advisory Board(Honoraria), Speaker(Honoraria); Happify – Consultant(Fees); Incyte – Advisory Board(Honoraria); Janssen Biotech – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Fees); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); LearnSkin – Speaker(Honoraria); Leo Pharma – Speaker(Honoraria); LEO Pharma, US – Advisory Board(Fees); Mindera – Investigator(Grants/Research Funding), Speaker(Honoraria); National Psoriasis Foundation – Speaker(Honoraria); Novartis – Advisory Board(Fees), Investigator(Grants/Research Funding); Ortho Dermatologics – Speaker(Honoraria); Oruka Therapeutics – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker/Faculty Education(Honoraria); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); Taxa – Consultant (1099 relationship)(Stock); UCB – Advisory Board(Fees), Speaker(Honoraria);
Lawrence J Green, MD, FAAD
Alphyn Biologics – Advisory Board(Honoraria); Amgen – Investigator(Honoraria), Speaker(Honoraria); Apogee BioPharm – Investigator(Grants/Research Funding); BMS – Investigator(Grants/Research Funding), Speaker(Honoraria); Dermavant Sciences, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Evoimmune – Investigator(Grants/Research Funding); Galderma – Speaker(Honoraria); Galderma USA – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Incyte – Investigator(Grants/Research Funding); Incyte Corporation – Speaker(Honoraria); Ipsen – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); Nutrafol – Advisory Board(Honoraria); Ortho Dermatologics – Investigator(Grants/Research Funding); Oruka Therapeutics – Investigator(Grants/Research Funding); Pelthos Therapeutics – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); UCB – Consultant(Honoraria); VeraDermics Inc. – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Investigator(Grants/Research Funding);
Elizabeth A. Kiracofe, MD, FAAD
Arcutis Biotherapeutics – Speaker(Fees); CeraVe – Consultant (1099 relationship)(Honoraria); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly – Speaker(Fees); Galderma – Speaker(Fees); Incyte Corporation – Speaker(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Speaker(Fees);
Marta Jane Van Beek, MD, MPH, FAAD
No financial relationships exist with ineligible companies.
Joseph Zabinski, PhD
No financial relationships exist with ineligible companies.